Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LNXSF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LNXSF and 80,000+ other tickers.
See exactly how LNXSF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LNXSF and 80,000+ other tickers.
LANXESS AG is a global producer and supplier of a diverse range of specialized chemical products, encompassing chemical intermediates, various additives, distinct specialty chemicals, and advanced plastics. The company's operations are strategically organized into four distinct divisions: Advanced Intermediates, Specialty Additives, Consumer Protection, and Engineering Materials. The Advanced Intermediates division delivers sophisticated industrial building blocks, fundamental and specialized chemical compounds, organometallic substances, and mineral-based pigments. These offerings serve a…
LANXESS Aktiengesellschaft (LNXSY) Q1 2026 Earnings Call Transcript
LANXESS Aktiengesellschaft (LNXSY) Q4 2025 Press Conference Call Transcript
LANXESS Aktiengesellschaft (LNXSY) Q4 2025 Earnings Call Transcript
Wynn Macau was a contributor during the quarter. The Hong Kong-based casino operator saw its stock price rise despite delivering underwhelming second-quarter 2025 results. Azimut Holdings was a contributor during the quarter. The Italian financials firm's stock price rose as it posted solid results during the period, in our view. Amplifon was a detractor during the quarter. The Italian hearing aid company's stock price plunged after first half results revealed that revenue grew more slowly than expected, and the company reduced its fiscal year guidance.
Lanxess shares plunged 14% after Q3/25 earnings, as guidance was cut to the lower end and all business units underperformed. LNXSF faces severe headwinds from Chinese dumping, US trade policies, weak demand, and uncertainty over the Envalior sale, fueling fears of further deleveraging challenges. Despite the crisis, Lanxess maintains steady EBITDA margins, demonstrates resilience, and could benefit from industry consolidation or asset sales.